Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine augmentation to SSRIs in OCD
IRCT20211121053132N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of memantine in obsessive compulsive disorder (OCD) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Change in obsessive-compulsive symptoms and Change in working memory. Started May 2024; status: completed.
02
Drugs
memantine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20211121053132N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211121053132N1.